Vaughan H A, McKenzie I F, Sandrin M S
Molecular Immunogenetics Laboratory, Austin Research Institute, Austin Hospital, Heidelberg, Victoria, Australia.
Transplantation. 1995 Jan 15;59(1):102-9. doi: 10.1097/00007890-199501150-00018.
The xenotransplantation of pig organs to humans is now receiving serious consideration because of the shortage of human donors for organ transplants. However, such xenografts would be hyperacutely rejected due to naturally occurring antibodies, present in all human sera, that react with pig antigens on the surface of endothelial cells, leading to complement fixation and the rapid onset of intravascular coagulation. A major target of these human natural antibodies is the terminal nonreducing disaccharide Gal alpha (1,3)Gal, and we now report on the array of molecules that are galactosylated by the alpha 1,3-galactosyltransferase. Pig lymphocytes and endothelial cells (both of which bear Gal alpha(1,3)Gal epitopes) were surface iodinated and the 125I-labeled molecules were precipitated with either human antibodies or the lectin from Griffonia simplicifolia (IB4, which binds to Gal alpha(1,3)Gal epitopes). The precipitated molecules were analyzed by gel electrophoresis and autoradiography. Five major groups of molecules were identified by one-dimensional SDS/PAGE (alpha 220 kDa, beta 160-180 kDa, gamma 120 kDa, delta 64 kDa, epsilon 40 kDa); the beta molecule was different in the 2 cell types (beta 1 of lymphocytes and beta 2 of endothelial cells). Two-dimensional SDS/PAGE analysis revealed that each of these groups of molecules resolved into further species of different charge (presumably due to different glycosylation) and also different molecular mass to give at least 20 different Gal alpha(1,3)Gal+ surface molecules. None of these molecules appeared to be present as disulfide-associated dimers. It is clear that there are many galactosylated molecules on the cell surface; indeed, using longer exposures of the autoradiographs, at least 40 different Gal alpha (1,3)Gal+ molecules could be identified. Several of these molecules are likely to have been identified by others, e.g., the 115-kDa, 125-kDa, and 135-kDa triad identified by Platt. Strategies to overcome hyperacute rejection could include modification or deletion of the alpha 1,3-galactosyltransferase gene, which would simultaneously delete all the Gal alpha(1,3)Gal epitopes on these molecules.
由于人体器官移植供体短缺,猪器官向人体的异种移植目前正受到认真考虑。然而,此类异种移植物会因所有人血清中天然存在的抗体而发生超急性排斥反应,这些抗体与内皮细胞表面的猪抗原发生反应,导致补体固定和血管内凝血迅速发生。这些人类天然抗体的一个主要靶标是末端非还原二糖Galα(1,3)Gal,我们现在报告由α1,3 -半乳糖基转移酶进行半乳糖基化修饰的一系列分子。猪淋巴细胞和内皮细胞(二者均带有Galα(1,3)Gal表位)进行表面碘化,然后用人类抗体或来自西非豆科植物的凝集素(IB4,其与Galα(1,3)Gal表位结合)沉淀125I标记的分子。通过凝胶电泳和放射自显影分析沉淀的分子。通过一维SDS/PAGE鉴定出五组主要分子(α 220 kDa、β 160 - 180 kDa、γ 120 kDa、δ 64 kDa、ε 40 kDa);β分子在两种细胞类型中有所不同(淋巴细胞的β1和内皮细胞的β2)。二维SDS/PAGE分析表明,这些分子组中的每一组都可进一步解析为电荷不同(可能由于糖基化不同)且分子量也不同的物种,从而产生至少20种不同的Galα(1,3)Gal +表面分子。这些分子似乎都不是以二硫键相关的二聚体形式存在。显然,细胞表面存在许多半乳糖基化分子;实际上,使用放射自显影片更长时间的曝光,可以鉴定出至少40种不同的Galα(1,3)Gal +分子。其中一些分子可能已被其他人鉴定出来,例如普拉特鉴定出的115 kDa、125 kDa和135 kDa三联体。克服超急性排斥反应的策略可能包括修饰或删除α1,3 -半乳糖基转移酶基因,这将同时删除这些分子上所有的Galα(1,3)Gal表位。